NO991186L - Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes - Google Patents

Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes

Info

Publication number: NO991186L
Authority: NO; Norway
Prior art keywords: diabetes; treatment; type; insulin resistance; leptin antagonists
Prior art date: 1996-09-20

Application number

NO991186A

Other languages

English (en)

Norwegian (no)

Other versions

NO991186D0 (no

Inventor

Johann Ertl

Gerald Preibisch

Guenter Mueller

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-20

Filing date

1999-03-11

Publication date

1999-03-11

1999-03-11 Application filed by Hoechst Ag filed Critical Hoechst Ag

1999-03-11 Publication of NO991186D0 publication Critical patent/NO991186D0/no

1999-03-11 Publication of NO991186L publication Critical patent/NO991186L/no

Links

208000001072 type 2 diabetes mellitus Diseases 0.000 title 2
206010022489 Insulin Resistance Diseases 0.000 title 1
102000016267 Leptin Human genes 0.000 title 1
108010092277 Leptin Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title 1
229940039781 leptin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Child & Adolescent Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO991186A 1996-09-20 1999-03-11 Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes NO991186L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19638487		1996-09-20
PCT/EP1997/005035 WO1998012224A1 (fr)	1996-09-20	1997-09-15	Utilisation d'antagonistes de la leptine pour le traitement de la resistance insulinique dans les diabetes non insulino-dependants

Publications (2)

Publication Number	Publication Date
NO991186D0 NO991186D0 (no)	1999-03-11
NO991186L true NO991186L (no)	1999-03-11

Family

ID=7806282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO991186A NO991186L (no)	1996-09-20	1999-03-11	Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes

Country Status (18)

Country	Link
US (1)	US6399745B1 (fr)
EP (1)	EP0956302A1 (fr)
JP (1)	JP2001500869A (fr)
KR (1)	KR20010029537A (fr)
CN (1)	CN1230966A (fr)
AR (1)	AR008444A1 (fr)
AU (1)	AU735178B2 (fr)
BR (1)	BR9711513A (fr)
CA (1)	CA2266585A1 (fr)
CZ (1)	CZ90999A3 (fr)
HU (1)	HUP9904023A3 (fr)
ID (1)	ID21861A (fr)
IL (1)	IL129057A0 (fr)
NO (1)	NO991186L (fr)
PL (1)	PL332458A1 (fr)
RU (1)	RU2201249C2 (fr)
WO (1)	WO1998012224A1 (fr)
ZA (1)	ZA978455B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1101112B1 (fr)	1998-07-28	2004-10-06	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Induction de genes mediee par la leptine
US6777388B1 (en)	1998-08-21	2004-08-17	Clf Medical Technology Acceleration Program, Inc.	Leptin-related peptides
US7208572B2 (en)	1998-08-21	2007-04-24	Albany Medical College	Leptin-related peptides
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1214351A2 (fr)	1999-09-22	2002-06-19	Genset	Procedes de criblage de composes qui modulent l'interaction de la lsr-leptine et utilisations de ces composes dans la prevention et le traitement des maladies liees a l'obesite
AU2001281784B2 (en)	2000-05-22	2005-09-15	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Receptor-based interaction trap
US7235629B2 (en)	2000-11-14	2007-06-26	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Functional fragment of the leptin receptor
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
RU2378285C2 (ru)	2004-02-11	2010-01-10	Амилин Фармасьютикалз, Инк.	Гибридные полипептиды с селектируемыми свойствами
US7407929B2 (en) *	2004-05-07	2008-08-05	Boston Biomedical Research Institute	Leptin peptide antagonists
US7423113B2 (en)	2004-08-25	2008-09-09	Vib Vzw	Leptin antagonist
BRPI0518241A (pt)	2004-11-01	2008-04-22	Amylin Pharmaceuticals Inc	métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
US8394765B2 (en) *	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US7575878B2 (en)	2004-11-18	2009-08-18	Vib Vzw	Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
US7307142B2 (en) *	2004-11-26	2007-12-11	Yissum Research And Development Company Of The Hebrew University Of Jerusalem	Leptin antagonists
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
JP2008530130A (ja)	2005-02-11	2008-08-07	アミリン・ファーマシューティカルズ，インコーポレイテッド	Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
EP2330125A3 (fr)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides ayant des propriétés sélectionnables
EP1922336B1 (fr)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Polypeptides hybrides presentant des proprietes selectionnables
JP2009530407A (ja) *	2006-03-23	2009-08-27	アミリン・ファーマシューティカルズ，インコーポレイテッド	代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2219664A1 (fr) *	2007-11-14	2010-08-25	Amylin Pharmaceuticals, Inc.	Procédés de traitement de l'obésité et de maladies et de troubles associés à l'obésité
US8778890B2 (en)	2009-03-31	2014-07-15	Temple University—Of the Commonwealth System of Higher Education	Leptin antagonist and methods of use
WO2010118384A2 (fr)	2009-04-10	2010-10-14	Amylin Pharmaceuticals, Inc.	Composés agonistes de l'amyline pour mammifères ayant une carence en oestrogènes
DK2621519T3 (en)	2010-09-28	2017-10-16	Aegerion Pharmaceuticals Inc	Leptin-ABD fusion polypeptides with improved duration of action
WO2013009539A1 (fr)	2011-07-08	2013-01-17	Amylin Pharmaceuticals, Inc.	Polypeptides manipulés présentant une durée d'action accrue et une immunogénicité réduite
HRP20181879T1 (hr)	2012-09-27	2019-02-08	The Children's Medical Center Corporation	Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
LT3074033T (lt)	2013-11-26	2019-02-25	The Children`S Medical Center Corporation	Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2015153933A1 (fr)	2014-04-03	2015-10-08	The Children's Medical Center Corporation	Inhibiteurs hsp 90 pour le traitement de l'obésité et leurs procédés d'utilisation
CN104829708B (zh) *	2015-05-06	2017-11-28	广东省生物资源应用研究所	一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh)	2015-05-06	2017-12-19	广东省生物资源应用研究所	一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (fr)	2015-07-23	2017-01-26	Universite De Strasbourg	Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie
EP3509624B1 (fr)	2016-09-12	2023-08-09	Amryt Pharmaceuticals Inc.	Procédés de détection d'anticorps neutralisants anti-leptine
WO2019043382A1 (fr) *	2017-08-31	2019-03-07	University Of Dundee	Peptides de leptine dérivés et leur utilisation pour le traitement des troubles neurologiques
CN119823265B (zh) *	2025-01-02	2026-01-06	江苏省农业科学院	抗leptin的单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2040926C1 (ru) *	1991-11-25	1995-08-09	Анатолий Григорьевич Гриценко	Способ лечения сахарного диабета
US6001968A (en) *	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) *	1994-08-17	2000-04-11	The Rockefeller University	OB polypeptides as modulators of body weight
US5563243A (en) *	1995-01-31	1996-10-08	Eli Lilly And Company	Anti-obesity proteins
US5525705A (en) *	1995-01-31	1996-06-11	Eli Lilly And Company	Anti-obesity proteins
US5521283A (en) *	1995-01-31	1996-05-28	Eli Lilly And Company	Anti-obesity proteins
US5569743A (en) *	1995-01-31	1996-10-29	Eli Lilly And Company	Anti-obesity proteins
US5574133A (en) *	1995-01-31	1996-11-12	Eli Lilly And Company	Anti-obesity proteins
WO1997002004A2 (fr) *	1995-06-30	1997-01-23	Eli Lilly And Company	Procedes pour le traitement du diabete
US7063958B1 (en) *	1996-01-16	2006-06-20	The Rockefeller University	Nucleic acids db, the receptor for leptin
US5922678A (en) *	1996-06-28	1999-07-13	Eli Lilly And Company	Methods for treating diabetes

1997
- 1997-09-15 ID IDW990105A patent/ID21861A/id unknown
- 1997-09-15 CA CA002266585A patent/CA2266585A1/fr not_active Abandoned
- 1997-09-15 AU AU44586/97A patent/AU735178B2/en not_active Ceased
- 1997-09-15 JP JP10514270A patent/JP2001500869A/ja active Pending
- 1997-09-15 BR BR9711513A patent/BR9711513A/pt not_active Application Discontinuation
- 1997-09-15 US US09/147,805 patent/US6399745B1/en not_active Expired - Fee Related
- 1997-09-15 CN CN97198076A patent/CN1230966A/zh active Pending
- 1997-09-15 KR KR1019997002389A patent/KR20010029537A/ko not_active Ceased
- 1997-09-15 PL PL97332458A patent/PL332458A1/xx unknown
- 1997-09-15 IL IL12905797A patent/IL129057A0/xx unknown
- 1997-09-15 HU HU9904023A patent/HUP9904023A3/hu unknown
- 1997-09-15 CZ CZ99909A patent/CZ90999A3/cs unknown
- 1997-09-15 EP EP97942929A patent/EP0956302A1/fr not_active Withdrawn
- 1997-09-15 RU RU99107759/14A patent/RU2201249C2/ru not_active IP Right Cessation
- 1997-09-15 WO PCT/EP1997/005035 patent/WO1998012224A1/fr not_active Ceased
- 1997-09-18 AR ARP970104293A patent/AR008444A1/es unknown
- 1997-09-19 ZA ZA9708455A patent/ZA978455B/xx unknown
1999
- 1999-03-11 NO NO991186A patent/NO991186L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1998012224A1 (fr)	1998-03-26
IL129057A0 (en)	2000-02-17
NO991186D0 (no)	1999-03-11
PL332458A1 (en)	1999-09-13
ID21861A (id)	1999-08-05
AU4458697A (en)	1998-04-14
CN1230966A (zh)	1999-10-06
AU735178B2 (en)	2001-07-05
JP2001500869A (ja)	2001-01-23
CA2266585A1 (fr)	1998-03-26
RU2201249C2 (ru)	2003-03-27
KR20010029537A (ko)	2001-04-06
CZ90999A3 (cs)	1999-06-16
AR008444A1 (es)	2000-01-19
BR9711513A (pt)	1999-08-24
EP0956302A1 (fr)	1999-11-17
ZA978455B (en)	1998-03-20
US6399745B1 (en)	2002-06-04
HUP9904023A2 (hu)	2000-03-28
HUP9904023A3 (en)	2002-01-28

Publication	Publication Date	Title
NO991186D0 (no)	1999-03-11	Bruk av leptinantagonister for behandling av insulinresistens ved type-II-diabetes
DE122004000049I1 (de)	2005-05-04	Neue Insulinderivate mit schnellem Wirkungseintritt.
DK0925083T3 (da)	2004-01-05	Engangssprøjte
FI945281A7 (fi)	1995-05-11	Heterosykliset yhdisteet, niiden valmistus ja käyttö
FI955051L (fi)	1996-04-25	Heterosyklisiä yhdisteitä ja niiden valmistus ja käyttö
BR9612678A (pt)	1999-07-20	Seringa descartável
EG21712A (en)	2002-02-27	Treatment of insulin resistance
HUP0003428A3 (en)	2001-12-28	Use of leptin antagonists for the treatment of diabetes
NO990097D0 (no)	1999-01-11	Ny behandling av leptin-resistens
NO975718D0 (no)	1997-12-05	Behandling av insulinresistens
FI954229L (fi)	1995-09-08	Heterosykliset yhdisteet, niiden käyttö ja valmistus
FI963130L (fi)	1996-10-09	Heterosykliset yhdisteet sekä niiden valmistus ja käyttö
HUP0103262A3 (en)	2004-03-01	Medicament containing platinum complex compounds and the use thereof
EE200000712A (et)	2002-04-15	Eeltäidetud süstal ja selle kasutamine
NO995940D0 (no)	1999-12-03	Anvendelse av leptin antagonister for behandling av diabetes
PL337220A1 (en)	2000-08-14	Application of leptin antagonists in treating diabetes
HK1027742A (en)	2001-01-23	Use of leptin antagonists for the treatment of diabetes
ES1039049Y (es)	1999-03-16	Jeringuilla desechable perfeccionada.
BR7401733U (pt)	1998-08-04	Seringa travável descartável
ES1033974Y (es)	1997-10-16	Jeringuilla perfeccionada.
BR9601744A (pt)	1997-03-18	Seringa descartável aperfeiçoada
IT243703Y1 (it)	2002-03-05	Siringa perfezionata
ES1037202Y (es)	1998-06-16	Jeringuilla desechable perfeccionada.
NO965463D0 (no)	1996-12-18	Spröyte
KR970049031U (ko)	1997-08-12	세척기

Legal Events

Date	Code	Title	Description
2005-06-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application